Nasdaq
$31.73▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $31.0MShares out 1.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.14After-hours26.10.15 05:38SCHEDULE 13GOwnership#●●●#●●●
IRulya Therapeutics Inc.
Foresite Capital Fund VI LP has filed a SCHEDULE 13G to report its beneficial ownership in IRulya Therapeutics Inc. The firm has been registered as a significant shareholder, indicating a change in the company's major shareholder structure.…more
$31.73+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:00SCHEDULE 13GOwnership
IRulya Therapeutics Inc.
Perceptive Advisors LLC has filed a Schedule 13G regarding its beneficial ownership in IRulya Therapeutics Inc. This filing serves to disclose the institutional investor's stake in the company to the market.…more
$31.73+0.00%vs prev closeView filingShare - 10.9Pre-market26.10.09 20:598-KKey event
IRulya Therapeutics Inc.
Quince Therapeutics, Inc.
Quince Therapeutics will change its corporate name to IRulya Therapeutics Inc. effective October 9, 2026, following a major leadership and board restructuring. CEO Dirk Thye and COO Brendan Hannah have resigned, with Brigette Roberts appointed as the new CEO and John Militello as the new CFO.…more
$31.73+0.00%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 21:00#●●●#●●●#●●●
Quince Therapeutics Rebrands as IRulya Therapeutics to Focus on LAM-001 Clinical Development…more
Quince Therapeutics has rebranded as IRulya Therapeutics, shifting its strategic focus to the clinical development of its pulmonary disease candidate, LAM-001. The company has also completed a merger and leadership transition, with current cash reserves expected to fund operations through 2028.…more
$31.73+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 21:00
●●●●●●●● ●●●●● ●●●●●●
Quince Therapeutics will host a virtual key opinion leader event on September 28 to discuss the clinical landscape and therapeutic potential of its LAM-001 candidate. The event focuses on sharing insights regarding the drug's mechanism and ongoing development progress for pulmonary conditions.…more
$31.73+0.00%vs prev close - 9.4Pre-market26.09.04 21:33
●●●●●●●● ●●●●● ●●●●●●
Quince Therapeutics has been notified by Nasdaq of noncompliance with listing requirements. The company has until October 15 to regain compliance to avoid potential delisting.…more
$31.73+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report